JP2019521184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521184A5 JP2019521184A5 JP2019517750A JP2019517750A JP2019521184A5 JP 2019521184 A5 JP2019521184 A5 JP 2019521184A5 JP 2019517750 A JP2019517750 A JP 2019517750A JP 2019517750 A JP2019517750 A JP 2019517750A JP 2019521184 A5 JP2019521184 A5 JP 2019521184A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective
- patient
- amount
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 3
- 210000000577 adipose tissue Anatomy 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 229940116269 uric acid Drugs 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229940016667 resveratrol Drugs 0.000 claims 2
- 235000021283 resveratrol Nutrition 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000001120 cytoprotective effect Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172339P | 2015-06-08 | 2015-06-08 | |
| US15/176,422 | 2016-06-08 | ||
| US15/176,422 US10285963B2 (en) | 2015-06-08 | 2016-06-08 | Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases |
| MXMX/A/2017/007448 | 2017-06-07 | ||
| MX2017007448A MX365886B (es) | 2015-06-08 | 2017-06-07 | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas. |
| PCT/MX2017/000061 WO2017213486A2 (es) | 2016-06-08 | 2017-06-08 | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521184A JP2019521184A (ja) | 2019-07-25 |
| JP2019521184A5 true JP2019521184A5 (enExample) | 2020-07-27 |
Family
ID=57450744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517750A Pending JP2019521184A (ja) | 2015-06-08 | 2017-06-08 | 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10285963B2 (enExample) |
| JP (1) | JP2019521184A (enExample) |
| CN (1) | CN109890369B (enExample) |
| BR (1) | BR112018075395A2 (enExample) |
| CA (1) | CA3027048A1 (enExample) |
| ES (1) | ES2988151T3 (enExample) |
| MX (1) | MX365886B (enExample) |
| RU (1) | RU2749950C2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470060B1 (en) * | 2016-06-08 | 2024-07-31 | Astudillo De La Vega, Horacio | Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006273834A (ja) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ａｍｐｋ活性化剤 |
| US7709539B2 (en) * | 2004-08-11 | 2010-05-04 | Chang Gung University | Therapeutic use of resveratrol for hyperglycemia |
| ITPD20050224A1 (it) * | 2005-07-19 | 2007-01-20 | Actimex Srl | Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego |
| WO2007035612A2 (en) * | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
| JPWO2008143182A1 (ja) * | 2007-05-17 | 2010-08-05 | 株式会社カネカ | 甘草ポリフェノールを含有する組成物 |
| JP5594819B2 (ja) * | 2009-12-22 | 2014-09-24 | キリンホールディングス株式会社 | 脂質代謝改善用組成物 |
| JP2012041296A (ja) * | 2010-08-19 | 2012-03-01 | Medience Corp | 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品 |
| EP3466418A1 (en) * | 2011-07-15 | 2019-04-10 | NuSirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
-
2016
- 2016-06-08 US US15/176,422 patent/US10285963B2/en active Active
-
2017
- 2017-06-07 MX MX2017007448A patent/MX365886B/es active IP Right Grant
- 2017-06-08 ES ES17810608T patent/ES2988151T3/es active Active
- 2017-06-08 BR BR112018075395-5A patent/BR112018075395A2/pt not_active Application Discontinuation
- 2017-06-08 CN CN201780046806.6A patent/CN109890369B/zh active Active
- 2017-06-08 JP JP2019517750A patent/JP2019521184A/ja active Pending
- 2017-06-08 RU RU2018147077A patent/RU2749950C2/ru active
- 2017-06-08 CA CA3027048A patent/CA3027048A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2981782T3 (es) | Composiciones y métodos para tratar la inflamación crónica y enfermedades inflamatorias | |
| US10517856B2 (en) | Methods of altering programmed cell death and extending cell life | |
| JP7613776B2 (ja) | 経皮送達製剤 | |
| KR20200016889A (ko) | 과다 졸림증을 치료하기 위한 방법 및 조성물 | |
| JP2008538586A5 (enExample) | ||
| JP2011522876A (ja) | 永続性心房細動を予防するためのドロネダロン | |
| Melling et al. | A model of poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise training | |
| JP2009544665A5 (enExample) | ||
| ES2773834T5 (es) | Métodos y composiciones para tratar la depresión usando ciclobenzaprina | |
| JP2016540827A (ja) | ミトコンドリア疾患を治療するためのシステアミン及びその誘導体の使用 | |
| JP5482999B2 (ja) | 体温低下抑制剤 | |
| Ermolova et al. | Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients | |
| JP2010532348A5 (enExample) | ||
| JP2019521184A5 (enExample) | ||
| Schmidt et al. | Remote ischemic preconditioning with–but not without–metabolic support protects the neonatal porcine heart against ischemia-reperfusion injury | |
| US8435963B2 (en) | Weight loss compositions and uses thereof | |
| JP2007517911A (ja) | 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法 | |
| Tizzano et al. | The Triple Uptake Inhibitor (1 R, 5 S)-(+)-1-(3, 4-Dichlorophenyl)-3-azabicyclo [3.1. 0] Hexane Hydrochloride (DOV 21947) Reduces Body Weight and Plasma Triglycerides in Rodent Models of Diet-Induced Obesity | |
| JP2011510944A (ja) | テトラヒドロピリミジンの使用 | |
| RU2018147077A (ru) | Комбинация метаболических биоэнергетических и нутра-эпигенетических регуляторов, нутрицевтических соединений в традиционных и нанотехнологических комбинациях для возвращения в прежнее состояние и предотвращения хронического повреждения, ускоренного клеточной чувствительностью, вызванной сахарным диабетом и другими дегенеративными хроническими комплексными заболеваниями | |
| CN103110609A (zh) | 一种治疗口腔溃疡的涂膜剂及其制备方法 | |
| CN101991573A (zh) | 去氢钩藤碱及其异构体在制备药物中的用途 | |
| WO2019152765A1 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and signaling | |
| JP6100510B2 (ja) | 抗感冒剤 | |
| CN107205944A (zh) | 用于纠正衰弱和/或慢性疲劳综合征的症状或治疗衰弱和/或慢性疲劳综合征的药物组合物 |